New horizons in osteoporosis therapies

T Harsløf, BL Langdahl - Current opinion in pharmacology, 2016 - Elsevier
Highlights•Odanacatib is a new antiresorptive therapy with documented anti-fracture
efficacy.•Romosozumab is a new bone anabolic treatment that also inhibits resorption.• …
被引用次数：49 相关文章

New horizons in osteoporosis therapies

T Harsløf, BL Langdahl - Current Opinion in Pharmacology, 2016 - infona.pl
Efficient therapies are available for the treatment of osteoporosis, however, there are still
unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain …

New horizons in osteoporosis therapies.

T Harsløf, BL Langdahl - Current Opinion in Pharmacology, 2016 - europepmc.org
Efficient therapies are available for the treatment of osteoporosis, however, there are still
unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain …

New horizons in osteoporosis therapies

T Harsløf, BL Langdahl - Current opinion in pharmacology, 2016 - pubmed.ncbi.nlm.nih.gov
Efficient therapies are available for the treatment of osteoporosis, however, there are still
unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain …

New horizons in osteoporosis therapies

T Harsløf, BL Langdahl - Current Opinion in Pharmacology, 2016 - pure.au.dk
Efficient therapies are available for the treatment of osteoporosis, however, there are still
unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain …

[引用][C] New horizons in osteoporosis therapies

T Harsløf, BL Langdahl - Current Opinion in Pharmacology, 2016 - cir.nii.ac.jp
New horizons in osteoporosis therapies | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす …